An antibody-drug conjugate given concurrently with stereotactic radiotherapy to treat brain metastases may increase patients' risk for symptomatic radiation necrosis, a study suggests.
Source: https://www.medscape.com/viewarticle/998023?src=mbl_msp_android&ref=share